

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that a potent aldosterone synthase inhibitor (SYH2072 tablets) (the “**Product**”), a Class 1 new chemical drug developed by the Group, has obtained approval from the U.S. Food and Drug Administration to conduct clinical trials in the U.S. The Product also obtained approval from the National Medical Products Administration of the People’s Republic of China in December 2025 to conduct clinical trials in China.

The Product is a highly selective and potent aldosterone synthase inhibitor (ASI) that effectively reduces plasma aldosterone levels without affecting cortisol levels. The indications for this clinical trial approval are uncontrolled hypertension and resistant hypertension. Pre-clinical studies indicated that the Product selectively inhibited aldosterone synthase activity, significantly reduced plasma aldosterone levels in animal disease models, and dose-dependently lowered blood pressure in hypertensive models while having no impact on cortisol levels. With favourable pharmacokinetic properties and safety profile, the Product had the potential to become a best-in-class therapy. Currently, the Group has submitted multiple patent applications for the Product in China and overseas.

Given the substantial unmet clinical need for aldosterone synthase inhibitors, the Product has high clinical development value and is expected to provide a new treatment option for patients with uncontrolled hypertension and resistant hypertension.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 13 January 2026

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong, as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.*